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Abstract
Background: Epidemiological studies have shown direct associations between type 2 diabetes and obesity, both
conditions associated with hyperglycaemia and hyperinsulinemia, and the risk of pancreatic cancer. Up to 80% of
pancreatic cancer patients present with either new-onset type 2 diabetes or impaired glucose tolerance at the time
of diagnosis. Recent population studies indicate that the incidence of pancreatic cancer is reduced among diabetics
taking metformin. In this study, the effects of exposure of pancreatic cancer cells to high glucose levels on their
growth and response to metformin were investigated.
Methods: The human pancreatic cancer cell lines AsPC-1, BxPC-3, PANC-1 and MIAPaCa-2 were grown in normal
(5 mM) or high (25 mM) glucose conditions, with or without metformin. The influence by metformin on
proliferation, apoptosis and the AMPK and IGF-IR signalling pathways were evaluated in vitro.
Results: Metformin significantly reduced the proliferation of pancreatic cancer cells under normal glucose
conditions. Hyperglycaemia however, protected against the metformin-induced growth inhibition. The
anti-proliferative actions of metformin were associated with an activation of AMP-activated protein kinase
AMPKThr172 together with an inhibition of the insulin/insulin-like growth factor-I (IGF-I) receptor activation
and downstream signalling mediators IRS-1 and phosphorylated Akt. Furthermore, exposure to metformin
during normal glucose conditions led to increased apoptosis as measured by poly(ADP-ribose) polymerase
(PARP) cleavage. In contrast, exposure to high glucose levels promoted a more robust IGF-I response and
Akt activation which correlated to stimulated AMPKSer485 phosphorylation and impaired AMPKThr172
phosphorylation, resulting in reduced anti-proliferative and apoptotic effects by metformin.
Conclusion: Our results indicate that metformin has direct anti-tumour activities in pancreatic cancer cells
involving AMPKThr172 activation and suppression of the insulin/IGF signalling pathways. However,
hyperglycaemic conditions enhance the insulin/IGF-I responses resulting in an altered AMPK activation
profile and prevent metformin from fully switching off the growth promoting signals in pancreatic
cancer cells.
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Background
Over recent decades the incidence of metabolic disorders,
such as obesity and type 2 diabetes mellitus, has increased
as a consequence of westernized lifestyle and changes
in diet. These conditions are in turn associated with an
increased risk of developing cancer [1-3]. Epidemiological
studies have demonstrated that obesity and type 2 diabetes
are among the top three modifiable risk factors for
pancreatic cancer [2,4-8]. Almost 80% of pancreatic
cancer patients present with either new-onset type 2
diabetes or impaired glucose tolerance at the time of
diagnosis [9,10]. The relationship between type 2 diabetes
and pancreatic cancer is complex and it remains unclear
whether type 2 diabetes contributes to the development of
pancreatic cancer or if precancerous cells cause the
diabetes. Individuals with elevated fasting glucose and
glycated haemoglobin (HbA1c) levels [11,12], or with
higher c-peptide or insulin levels have a two to four-fold
increase in the risk of pancreatic cancer [1,7]. Type 2
diabetes patients also demonstrate an increased risk of
pancreatic cancer-related death as compared with those
without diabetes [13]. Type 2 diabetes is characterized
by hyperglycaemia and peripheral insulin resistance with
compensatory hyperinsulinemia. Aside from its metabolic
actions, insulin can mediate direct mitogenic effects
through the insulin receptor (IR) and insulin-like growth
factor I (IGF-I) receptor (IGF-IR). Insulin may also affect
the cancer risk indirectly via increased production and
bioavailability of IGF-I [6,14]. Additionally, hyperglycaemia
can increase the sensitivity to IGF-I [4], thereby enhancing
its mitogenic potential and providing an additional link
between type 2 diabetes and cancer.
Insulin-sensitizing and glucose lowering drugs, such as
metformin, are used as first-line treatment in the
management of type 2 diabetes to improve glycaemic
control in patients with insulin resistance. The key
metabolic action of metformin involves the inhibition
of hepatic glucose secretion, which consequently decreases
the hyperinsulinemia. This mechanism is mediated via
activation of the energy-sensing AMP-activated protein
kinase (AMPK) in hepatocytes, through the liver kinase
B1 (LKB1) signalling pathway [15]. Although metformin
can lower blood glucose, the levels rarely remain within
the normal range and as the type 2 diabetes progresses,
additional medication such as exogenous insulin is often
required to control patients’ hyperglycaemia [16,17]. In
addition to its anti-diabetic effects, metformin has
recently been postulated to have a protective role against
cancer. Epidemiological and retrospective studies have
demonstrated that diabetic patients taking metformin
not only have a lower incidence of pancreatic cancer,
but also an improved cancer outcome [18-21]. The
indicated anti-neoplastic activity of metformin may
relate to reduced plasma insulin concentrations or by
direct effects on the tumour cells. Recent studies
suggest that metformin-induced AMPK activation at
Thr172 inhibits the central growth control node mam-
malian target of rapamycin mTOR, thus preventing
protein synthesis and cell proliferation [22]. Metformin
has recently been shown to possess anti-tumour
effects, both in AMPK-dependent and independent
manners [23-25].
Although an increasing number of studies demonstrate
the anti-tumour effects of metformin, relatively little is
known about the effects and underlying mechanisms of
metformin on pancreatic cancer cells. The goal of this
study was to examine the direct effects of metformin on
human pancreatic cancer cells in the context of normal or
elevated glucose levels. Effects on proliferation, apoptosis,




All chemicals and reagents were purchased from Sigma
Aldrich (St. Louis, Mo, USA) unless stated otherwise. Cell
culture media, penicillin/streptomycin and fetal bovine
serum (FBS) were purchased from Invitrogen (Paisley,
UK). IGF-I was purchased from GroPep (Adelaide,
Australia). MTT; Cell Proliferation Kit I was derived from
Roche (Mannheim, Germany). Anti-cleaved PARP, anti-
phospho-AMPKThr172, anti-phospho-AMPKSer485, anti-
AMPK, anti-IRS-1, anti-phospho-IGF-IRβ/phospho-IRβ,
anti-phospho-AktSer473 and anti-Akt antibodies were
purchased from Cell Signaling Technology Inc. (Beverly,
MA, USA). Anti-IGF-IRβ was obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) and anti-GAPDH
from Millipore (Temecula, CA, USA).
Cell culture
The human pancreatic adenocarcinoma cell lines AsPC-1,
BxPC-3, PANC-1 and MIAPaCa-2 were purchased from
ATCC-LGC Standards (Manassas, VA, USA). The cells
were maintained in RPMI1640 or DMEM supplemented
with 10% FBS and antibiotics (100 U/ml penicillin and 100
μg/ml streptomycin) in a humified 5% CO2 atmosphere at
37°C. All experiments were performed in glucose-free
RPMI1640 or DMEM supplemented with 5 mM (normal)
or 25 mM (high) D-glucose, 2 mM L-glutamine and
antibiotics as above (serum-free media; SFM), unless
stated otherwise.
MTT proliferation assay
Cells were plated (10 × 103 cells/well) in 96-well plates
in growth media with 5 mM glucose for 24 h before
switching to SFM with 5 mM or 25 mM glucose for
another 24 h. Cells were subsequently dosed with
increasing concentrations of metformin (0–20 mM) in
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SFM with 5 mM or 25 mM glucose in sextuplicates
(n = 6 wells). SFM with either 5 mM or 25 mM was
used as control. Following incubation for 24–72 h, cell
proliferation was assessed by MTT according to the
manufacturer’s instructions. The samples were measured on
a Labsystems Multiskan Plus plate reader (test wavelength
595 nm, reference wavelength 660 nm) using the DeltaSoft
JV software (BioMetallics Inc., Princeton, NJ, USA).
Western immunoblotting
Cells were cultured (6 × 105 cells/well) in 6-well plates
for 24 h. After an additional 24 h in normal glucose
SFM, the cells were dosed with metformin (0–20 mM)
in SFM or 1% FBS SFM with 5 or 25 mM glucose for 24 h.
Cells were then spiked with IGF-I (100 ng/ml) as indicated
for the final 15 min of incubation. Cells were lysed
as previously described [26]. Protein concentrations
were determined using BCA protein assay reagent kit
(ThermoFisherScientific, Waltham, MA, USA). Lysates
were dissolved in Laemmli buffer, boiled for 5 minutes and
separated (60–65 μg protein per lane) by SDS-PAGE (8% or
12%) and transferred to 0.2 μm Hybond-C extra nitrocellu-
lose membrane (Amersham Biosciences, Buckinghamshire,
UK). The membranes were blocked with 5% (w/v) milk
in Tris-buffered saline Tween-20 (TBST) and probed
overnight (4°C) with the indicated antibodies, all used at
dilutions of 1:1000. Immunoblotted proteins were detected
using HRP-conjugated secondary antibodies and visual-
ized by SuperSignal West Extended Duration Substrate
(ThermoFisherScientific) using BioRad Chemidoc XRS +
system and Image lab software.
Statistical analysis
Proliferation data are expressed as means ± SE of six
replicate wells. Densitometry analyses of Western blot
data were performed using Image J software (NIH, USA)
and are expressed as means ± SE of three individual exper-





































































































Figure 1 Metformin acts as a growth inhibitor for human pancreatic cancer cells. (A) BxPC-3, (B) MIAPaCa-2, (C) PANC-1 and (D) AsPC-1
pancreatic cancer cells were seeded in 96-well plates in normal (5 mM) glucose-containing growth media with 10% FBS for 24h, followed by 24 h
in 5 mM glucose-containing SFM. The cells were then dosed with or without metformin in normal glucose SFM for an additional 24 h. Results are
shown as percentage of SFM control and represent mean ± SE of six replicate wells. P-values are based on one-way ANOVA with Bonferroni post
hoc test. N.S., not significant. One representative out of three independent experiments is shown.
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performed by one- or two-way ANOVA with Bonferroni
post hoc test using GraphPad prism software. A P-value
of <0.05 was considered statistically significant.
Results
Metformin acts as a growth inhibitor for human
pancreatic cancer cells
To examine the effect of metformin on cell proliferation, a
panel of human pancreatic cancer cell lines were exposed
to metformin for 24 h in normal glucose levels (5 mM).
Metformin induced a significant 20-40% growth inhibition
of BxPC-3 (P < 0.001; Figure 1A), MIAPaCa-2 (P < 0.001;
Figure 1B) and PANC-1 (P < 0.01; Figure 1C), whereas
no growth inhibitory effect was observed on AsPC-1
pancreatic cancer cells (Figure 1D).
Hyperglycaemia suppresses metformin-induced growth
inhibition
The influence of increased levels of glucose on the sensitiv-
ity to metformin was examined. When BxPC-3 and
5 25














































































































Figure 2 High glucose reduces metformin-induced growth suppression and apoptosis. (A) BxPC-3 and (B) MIAPaCa-2 cells were
treated with or without 10 mM metformin in normal (5 mM) or high (25 mM) glucose-containing SFM for 72 h and proliferation was
assessed by MTT assay. Graphs represent changes in proliferation and mean ± SE of six replicate wells are depicted. P < 0.05, two-way
ANOVA with Bonferroni post hoc test. N.S., not significant. (C) BxPC-3 and (D) MIAPaCa-2 cells were treated in 1% FBS SFM with either 5
or 25 mM glucose, with or without metformin for 24 h and processed for levels of cleaved PARP as an indicator of apoptosis by Western
immunoblotting. Histograms show densitometry evaluation of relative difference in cleaved PARP intensity and represent means ± SE of
three independent experiments. P-values are based on two-way ANOVA with Bonferroni post hoc test. Blots shown are representative
assays from three independent experiments.
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MIAPaCa-2 cells were exposed to metformin for 72 h
under hyperglycaemic conditions (25 mM), the prolifera-
tion was decreased by 18% and 32%, respectively. Hypergly-
caemia significantly reduced the efficacy of metformin as
compared with normal (5 mM) glucose levels where a 56%
and 95% growth inhibition was obtained in BxPC-3 and
MIAPaCa-2, respectively (P < 0.001; Figure 2A, B). The
growth inhibitory effects by metformin in normal glucose
conditions correlated with a significant induction of cleaved
PARP, as an indicator of apoptosis (P < 0.05; Figure 2C, D).
In contrast, levels of cleaved PARP in response to
metformin were significantly decreased or absent at high
glucose conditions, consistent with the reduced sensitivity
of BxPC-3 and MIAPaCa-2 to metformin.
Hyperglycaemia impairs pAMPKThr172, but not pAMPKSer485
activation
To determine if the reduced efficacy of metformin during
hyperglycaemic conditions was related to altered AMPK
activation, metformin-stimulated AMPK phosphorylation
in BxPC-3 and MIAPaCa-2 cells during normal or high
glucose conditions was examined. These results show that
metformin stimulated AMPKThr172 phosphorylation in
cells cultured in normal glucose (P < 0.01; Figure 3A, B,
D, E). In BxPC-3 cells, metformin-induced AMPKThr172
phosphorylation corresponded to a decrease in basal
AMPKSer485 phosphorylation (Figure 3A-C). In contrast,
exposure to hyperglycaemic conditions inhibited both
basal and metformin-stimulated pAMPKThr172 increase,
whereas AMPKS485 phosphorylation remained stable. In
MIAPaCa-2, metformin induced both AMPKThr172 and
AMPKSer485 phosphorylation in 5 mM glucose (P < 0.01;
Figure 3D-F). However, exposure to 25 mM glucose
almost completely inhibited the metformin-induced
increase in AMPKThr172 phosphorylation, while AMPKSer485
phosphorylation was still present, similar to the effects
observed in BxPC-3.
Metformin modulates IRS-1 levels and Akt
phosphorylation
Having shown that high levels of glucose altered the
responsiveness to metformin and influenced the AMPK
activation pattern, we then examined the involvement













































































































































Figure 3 Hyperglycaemia impairs pAMPKThr172, but not pAMPKSer485 activation. (A-C) BxPC-3 and (D-F) MIAPaCa-2 cells were treated with
or without metformin in normal (5 mM) or high (25 mM) glucose-containing media with 1% FBS for 24 h and processed for immunoblot analysis
using antibodies against pAMPKThr172, pAMPKSer485 and AMPK. GAPDH is shown as a loading control. Graphs display densitometry measurements
of relative levels of AMPK protein phosphorylation at 5 mM (black bars) or 25 mM (striped bars) glucose conditions and represent means ± SE of
three independent experiments. P-values are based on two-way ANOVA with Bonferroni post hoc test. N.S. not significant. One representative
blot from three independent experiments is shown.
Karnevi et al. BMC Cancer 2013, 13:235 Page 5 of 11
http://www.biomedcentral.com/1471-2407/13/235
Figure 4, metformin exposure resulted in a significant
decrease in basal levels of IRS-1 (P < 0.05) and AktSer473
(P < 0.01) phosphorylation in a dose-dependent manner
during normal glucose conditions. In contrast, a high
glucose environment counteracted the metformin-mediated
IRS-1 and pAkt suppression in BxPC-3 (Figure 4A) and
MIAPaCa-2 (Figure 4B).
IGF-I and hyperglycaemia enhance AMPKSer485
phosphorylation
Having found that metformin influenced the IGF-I
signalling mediators under normal glucose levels, we next
addressed the influence by IGF-I on AMPK activation. No
changes in the basal or metformin-induced phosphoryl-
ation of AMPKThr172 were observed in response to IGF-I
stimulation at normal glucose (Figure 5A-B, D-E). Instead,
stimulation of BxPC-3 (Figure 5A, C) and MIAPaCa-2
(Figure 5D, F) cells with 100 ng/ml IGF-I caused a strong
phosphorylation of AMPKSer485. In hyperglycaemia, the
IGF-I-induced AMPKSer485 phosphorylation was sustained
in both cell lines. This suggested that exposure to IGF-I
in combination with higher glucose concentrations
stimulated AMPKSer485 phosphorylation, which shifted
the AMPKThr172 to AMPKSer485 balance.
Metformin inhibits IGF-I-stimulated IGF-IR and Akt activation
After studying the influence by IGF-I on AMPK activation,
we examined modulation of the IGF-IR pathway by
metformin. Interestingly, metformin potently inhibited the
activating phosphorylation of the IGF-IRβ/IRβ (P < 0.01),
and subsequently also the downstream phosphorylation of
Akt in both BxPC-3 (P < 0.01) and MIAPaCa-2 (P < 0.05)
cells at normal glucose levels (Figure 6). However, in the
hyperglycaemic situation, the IGF-I-mediated IGF-IRβ/IRβ
and Akt activation appeared to be more robust and
could override the inhibitory action of metformin. The
sustained IGF-IRβ/IRβ and Akt activation correlated
with the observed activation of AMPKSer485, supporting
the hypothesis of a link between the two pathways.
Discussion
Type 2 diabetes or impaired glucose tolerance frequently
occurs in pancreatic cancer patients. Compared to other
treatments, diabetic patients on metformin have a reduced













































































































Figure 4 Metformin modulates IRS-1 levels and Akt phosphorylation. (A-C) BxPC-3 and (D-F) MIAPaCa-2 cells were treated in 1% FBS SFM
with either normal (5 mM) or high (25 mM) glucose, with or without metformin for 24 h and processed for immunoblot analysis using antibodies
against IRS-1, pAkt and Akt. GAPDH is shown as a loading control. One representative blot is shown. Graphs display densitometry measurements
of relative levels of IRS-1 and pAkt at 5 mM (black bars) or 25 mM (striped bars) glucose conditions and represent means ± SE of three
independent experiments. P-values are based on two-way ANOVA with Bonferroni post hoc test. N.S. not significant.
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cancer, including pancreatic cancer [19-21]. However, the
molecular relationships underlying the metabolic and
suggested anti-cancer actions of metformin remain poorly
understood. Additionally, the importance of optimal
glucose control for the anti-tumour effects of metformin
has not been fully established. In this study, we describe
direct anti-proliferative actions by metformin using in vitro
models of pancreatic cancer. In addition, we demonstrate
that elevated glucose levels impair AMPK activation and
reduce the efficacy of metformin. Importantly, we show a
novel role for metformin on human pancreatic cancer
cells that may contribute to its indicated anti-cancer
actions among type 2 diabetic patients.
Metformin is believed to act mainly through activation
of the energy-conserving LKB1-AMPK pathway. Physio-
logical activation of the AMPK metabolic checkpoint in
response to nutrient depletion and energy stress suppresses
energy-consuming cellular processes such as protein
synthesis and cell division. We found that metformin
during normal glucose conditions significantly reduced
proliferation and promoted apoptosis through PARP cleav-
age in pancreatic cancer cells with functional LKB1
(MIAPaCa-2, BxPC-3 and PANC-1), while being incapable
of suppressing growth under the same conditions in AsPC-1
pancreatic cancer cells. AsPC-1 cells have previously been
reported to carry an epigenetic inactivation of LKB1 [27].
Our findings are consistent with prior observations,
showing pro-apoptotic actions on breast cancer cells
[28,29] and that a functional LKB1 was required for the
in vitro anti-proliferative effect of metformin [25,30].
Previous work indicates that metformin functions by
activating AMPK at Thr172 with subsequent downstream
inhibition of the growth promoting PI3K/Akt/mTOR
pathway [29,31,32]. Similarly, we also found the growth
inhibitory properties of metformin to be associated with
the activation of AMPKThr172 in pancreatic cancer cells.
Under hyperglycaemic conditions, the efficacy of metformin
was reduced with less anti-proliferative and pro-apoptotic
activity observed. Other investigators have reported
that lung and colon carcinoma cells were more sensitive
to metformin-induced growth inhibition at low glucose
concentrations, while no significant effect of metformin on
cell death was observed in high glucose conditions [30].
Similarly, a recent study demonstrated anti-proliferative
effects on pancreatic cancer cells by metformin at the low
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Figure 5 IGF-I and hyperglycaemia enhance pAMPKSer485 phosphorylation. (A-C) BxPC-3 and (D-F) MIAPaCa-2 cells were treated in normal
(5 mM) or high (25 mM) glucose-containing SFM, with or without 10 mM metformin for 24 h. Cells were spiked with IGF-I (100 ng/ml) as
indicated for the final 15 min prior to being lysed and processed for pAMPKThr172, pAMPKSer485 and AMPK abundance by Western
immunoblotting. GAPDH is shown as loading control. One representative blot is shown. Graphs display densitometry measurements of relative levels
at 5 mM (black bars) or 25 mM (striped bars) glucose conditions and represent means ± SE of two (B) or three (A, C-D) independent experiments.
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[33]. This study is in concordance with our data demon-
strating direct anti-tumour effects of metformin and sup-
ports our findings of enhanced sensitivity at physiological
normal glucose levels. We have now shown that the lower
anti-proliferative effect of metformin on pancreatic cancer
cells at higher glucose levels correlates to an impaired
AMPKThr172 activation and a shifted balance from
AMPKThr172 towards AMPKSer485 activation. The role of
AMPKSer485 in the complex AMPK signaling network is at
present not completely clear and conflicting reports exist.
A recent study indicated that endogenous protein kinase
A (PKA)-induced activation of AMPKSer485 in pancreatic
beta cells did not affect the phosphorylation status of
AMPKThr172. However, the activation of Thr172 and
Ser485 were inversely correlated in response to glu-
cose [34]. Other studies have proposed that PKB/Akt-
induced phosphorylation of AMPKSer485 can counteract
AMPKThr172 activation, thereby reducing the effects of
metformin [31,32,35].
Hyperinsulinemia with resulting increased circulating
levels of IGF-I have been suggested to play a role in
the connection between type 2 diabetes and cancer
[36]. Activation of the IR and IGF-IR result in receptor
autophosphorylation and recruitment of insulin receptor
substrate (IRS) 1, which in turn activates the PI3K/Akt
pathway leading to protein synthesis and cell survival [14].
The responsiveness to IGF-I can be enhanced by exposure
to high glucose concentrations [4], which may then
further promote cancer progression. In pancreatic cancer
cells, IGF-I stimulated a pronounced phosphorylation of
Akt and also AMPKSer485. However, at physiologically
normal glucose levels, IGF-I stimulated AMPKSer485 phos-
phorylation did not appear to antagonize pharmacological
activation of AMPKThr172 by metformin. Instead, we
established that metformin under these conditions
suppressed IGF-IR/IR phosphorylation causing a down-
stream inhibition of both basal and IGF-I stimulated
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Figure 6 Metformin inhibits IGF-I-stimulated IGF-IR and Akt activation in normal glucose. (A-C) BxPC-3 and (D-F) MIAPaCa-2 cells were
treated in normal (5 mM) or high (25 mM) glucose-containing SFM, with or without 10 mM metformin for 24 h. Cells were spiked with IGF-I
(100 ng/ml) as indicated for the final 15 min prior to lysis. pIGF-IRβ/pIRβ, IGF-IRβ, pAkt, and Akt were assessed by Western immunoblotting.
GAPDH is shown as loading control. One representative blot is shown. Graphs display densitometry measurements of relative levels at 5 mM
(black bars) or 25 mM (striped bars) glucose conditions and represent means ± SE of three independent experiments. P-values are based on
two-way ANOVA with Bonferroni post hoc test. N.S. not significant.
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via activation by its ligands transmits mitogenic signals
leading to the survival and proliferation of multiple
types of cancer. Mechanisms by which metformin inhibits
these pathways may thus contribute to the anti-tumour
effects previously observed in response to metformin.
Studies in other cell types have shown that during normal
glucose conditions, AMPKThr172 can phosphorylate inhibi-











































Figure 7 Overview of selected AMPK and IGF-IR signalling pathways relevant to this study in normal (A) and hyperglycaemic (B)
conditions. In normal conditions, metformin activates AMPKThr172 through the LKB1 signalling pathway. Activated AMPK inhibits cell growth by
repressing mTOR activity through activation of TSC2 and phosphorylation of inhibitory serine residues on IRS-1. In addition, as demonstrated in
the present study, metformin suppresses IGF-IR activation and reduces IRS-1 levels, which disable further signalling through the PI3K/Akt pathway.
During hyperglycaemia, signalling through the IGF-IR pathway appears more robust, leading to phosphorylation of Akt and AMPKSer485. This
inhibitory Ser485 site can inhibit activation of AMPKThr172, possibly contributing to the impaired growth inhibitory effect by metformin at high
glucose conditions.
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through the PI3K/Akt pathway [29,37]. However, studies
have also shown that Akt at high glucose conditions can
inhibit AMPK by phosphorylation of Ser485, which
prevents activation of Thr172 and thereby the action of
metformin [29,31,35,37,38]. In keeping with this, we ob-
served a strong activation of Akt and AMPKSer485 following
IGF-I stimulation at high glucose, which was sustained
after exposure to metformin. At high glucose, IGF-I
induced Akt and AMPKSer485 phosphorylation appeared
to correlate with a further reduction of the already-impaired
AMPKThr172 phosphorylation by metformin.
Conclusions
The findings of the current study using human pancreatic
cancer cells add novel information to the indications of
direct anti-tumour actions by metformin on transformed
epithelial cells. Metformin mediated its effects through
activation of AMPKThr172 together with inhibition of the
IR/IGF-IR signalling pathway (Figure 7). Hyperglycaemia,
with and without IGF-I, reduced the sensitivity to
metformin and counteracted the growth inhibitory effect
otherwise exerted by the drug. Our data suggests
that metformin may have beneficial effects on tumour
prevention or protection in non-diabetic patients with
normal glucose levels. Importantly, these data indicate
that optimizing glucose control in type 2 diabetic patients
may improve the beneficial anti-tumour actions provided
by metformin and should thus be further investigated.
Due to the strong associations between type 2 diabetes
and pancreatic cancer, evaluating the potential beneficial
effects by metformin, as well as the impact by different
glucose levels, should be considered of utmost importance.
Increased understanding of the relationship between the
two conditions may improve both future treatment
strategies as well as potentially providing possibilities of
novel early diagnostic approaches.
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